Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Prevention of PKG1α oxidation augments cardioprotection in the stressed heart
Taishi Nakamura, Mark J. Ranek, Dong I. Lee, Virginia Shalkey Hahn, Choel Kim, Philip Eaton, David A. Kass
Taishi Nakamura, Mark J. Ranek, Dong I. Lee, Virginia Shalkey Hahn, Choel Kim, Philip Eaton, David A. Kass
View: Text | PDF
Brief Report Cardiology

Prevention of PKG1α oxidation augments cardioprotection in the stressed heart

  • Text
  • PDF
Abstract

The cGMP-dependent protein kinase-1α (PKG1α) transduces NO and natriuretic peptide signaling; therefore, PKG1α activation can benefit the failing heart. Disease modifiers such as oxidative stress may depress the efficacy of PKG1α pathway activation and underlie variable clinical results. PKG1α can also be directly oxidized, forming a disulfide bond between homodimer subunits at cysteine 42 to enhance oxidant-stimulated vasorelaxation; however, the impact of PKG1α oxidation on myocardial regulation is unknown. Here, we demonstrated that PKG1α is oxidized in both patients with heart disease and in rodent disease models. Moreover, this oxidation contributed to adverse heart remodeling following sustained pressure overload or Gq agonist stimulation. Compared with control hearts and myocytes, those expressing a redox-dead protein (PKG1αC42S) better adapted to cardiac stresses at functional, histological, and molecular levels. Redox-dependent changes in PKG1α altered intracellular translocation, with the activated, oxidized form solely located in the cytosol, whereas reduced PKG1αC42S translocated to and remained at the outer plasma membrane. This altered PKG1α localization enhanced suppression of transient receptor potential channel 6 (TRPC6), thereby potentiating antihypertrophic signaling. Together, these results demonstrate that myocardial PKG1α oxidation prevents a beneficial response to pathological stress, may explain variable responses to PKG1α pathway stimulation in heart disease, and indicate that maintaining PKG1α in its reduced form may optimize its intrinsic cardioprotective properties.

Authors

Taishi Nakamura, Mark J. Ranek, Dong I. Lee, Virginia Shalkey Hahn, Choel Kim, Philip Eaton, David A. Kass

×

Figure 3

Protective effects of prevention of PKG1α C42 oxidation are related to changes in intracellular localization and TRPC6 targeting by the kinase.

Options: View larger image (or click on image) Download as PowerPoint
Protective effects of prevention of PKG1α C42 oxidation are related to c...
(A) Time-dependent myocyte PKG1α plasma membrane translocation and rediffusion with 10 μM H2O2 exposure in cells isolated from WT or PKG1αC42S hearts, representative of 3 experiments. Scale bar: 100 μm. (B) Localization disparities in PKG1α myocytes from TAC hearts in WT versus C42S-KI mice, representative of 30 cells (2 hearts) for each group. (C) Hypertrophic signaling from ET1 was blunted by TRPC3/6 blockade (503A) in NRCMs expressing WT PKG1α, but not when PKG activity was blocked by DT3. 503A did not alter the response in PKG1αC42S cells, whereas DT3 reversed the protection from C42S-mutant PKG1α cells. #P < 0.001 versus control and ET1 + 503A; †P < 0.05 versus ET1 + 503A; ‡P < 0.05 versus control. P values for 2-way ANOVA interaction between ET1 and genotype, P < 0.001; interaction between ET1 + 503A and genotype, P < 0.01. n = 7, control; n = 7–8, ET1; n = 6, ET1 + 503A; n = 3, ET1 + 503A + DT3. (D) Western blot for Cn expression and CaMKII and ERK1/2 phosphorylation after 48 hours of ET1 stimulation, with or without TRPC3/6 inhibition, in NRCMs (n = 6/group). See Supplemental Figure 12B for summary data. (E) NRCMs expressing PKG1αWT or PKG1αC42S and TRPC6WT or TRPC6T70A,S322Q (TRPC6mut). In PKG1αC42S-expressing cells, ET1 gene induction was blunted, but this was reversed by coexpressing TRPC6mut. n = 6/group. P values for 2-way ANOVA interaction between ET1 and TRPC6 (or PKG) genotype, *P < 0.001 versus respective controls.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts